Deoxybouvardin targets EGFR, MET, and AKT signaling to suppress non-small cell lung cancer cells

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

Extent: 1 Online-Ressource.

Language: Englisch

Bibliographic citation: Deoxybouvardin targets EGFR, MET, and AKT signaling to suppress non-small cell lung cancer cells ; volume:14 ; number:1 ; day:6 ; month:9 ; year:2024 ; pages:1-15 ; date:12.2024
Scientific reports ; 14, Heft 1 (6.9.2024), 1-15, 12.2024

Creator: Nam, A-Young
Joo, Sang Hoon
Khong, Quan T.
Park, Jisu
Lee, Na Yeong
Lee, Seung-On
Yoon, Goo
Park, Jin Woo
Na, MinKyun
Shim, Jung-Hyun

Contributor: SpringerLink (Online service)

DOI: 10.1038/s41598-024-70823-7

URN: urn:nbn:de:101:1-2411222110534.436571141829

Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 15.08.2025, 7:39 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Nam, A-Young
Joo, Sang Hoon
Khong, Quan T.
Park, Jisu
Lee, Na Yeong
Lee, Seung-On
Yoon, Goo
Park, Jin Woo
Na, MinKyun
Shim, Jung-Hyun
SpringerLink (Online service)

Other Objects (12)

Leukocyte Cell-Derived Chemotaxin 2 Retards Non-Small Cell Lung Cancer Progression Through Antagonizing MET and EGFR Activities

Deoxybouvardin-glucoside induces apoptosis in non-small cell lung cancer cells by targeting EGFR/MET and AKT signaling pathway

Combined inhibition of MET and VEGF enhances therapeutic efficacy of EGFR TKIs in EGFR-mutant non-small cell lung cancer with concomitant aberrant MET activation

Pharmacogenomics of EGFR-targeted therapies in non–small cell lung cancer: EGFR and beyond

Fatty acid synthase mediates EGFR palmitoylation in EGFR mutated non‐small cell lung cancer

Multicenter real-world analysis of combined MET and EGFR inhibition in patients with non-small cell lung cancer and acquired MET amplification or polysomy after EGFR inhibition

Isothiocyanates induce oxidative stress and suppress the metastasis potential of human non-small cell lung cancer cells

Association of integrin beta1 and c-MET in mediating EGFR TKI gefitinib resistance in non-small cell lung cancer

Targeting EGFR exon 20 insertion mutations in non-small cell lung cancer

EGFR transcriptionally upregulates UTX via STAT3 in non-small cell lung cancer

The EGFR-STYK1-FGF1 axis sustains functional drug tolerance to EGFR inhibitors in EGFR-mutant non-small cell lung cancer

Lentiviral vector-mediated RBM5 overexpression downregulates EGFR expression in human non-small cell lung cancer cells

Leukocyte Cell-Derived Chemotaxin 2 Retards Non-Small Cell Lung Cancer Progression Through Antagonizing MET and EGFR Activities

Deoxybouvardin-glucoside induces apoptosis in non-small cell lung cancer cells by targeting EGFR/MET and AKT signaling pathway

Combined inhibition of MET and VEGF enhances therapeutic efficacy of EGFR TKIs in EGFR-mutant non-small cell lung cancer with concomitant aberrant MET activation

Pharmacogenomics of EGFR-targeted therapies in non–small cell lung cancer: EGFR and beyond

Fatty acid synthase mediates EGFR palmitoylation in EGFR mutated non‐small cell lung cancer

Multicenter real-world analysis of combined MET and EGFR inhibition in patients with non-small cell lung cancer and acquired MET amplification or polysomy after EGFR inhibition

Isothiocyanates induce oxidative stress and suppress the metastasis potential of human non-small cell lung cancer cells

Association of integrin beta1 and c-MET in mediating EGFR TKI gefitinib resistance in non-small cell lung cancer

Targeting EGFR exon 20 insertion mutations in non-small cell lung cancer

EGFR transcriptionally upregulates UTX via STAT3 in non-small cell lung cancer

The EGFR-STYK1-FGF1 axis sustains functional drug tolerance to EGFR inhibitors in EGFR-mutant non-small cell lung cancer

Lentiviral vector-mediated RBM5 overexpression downregulates EGFR expression in human non-small cell lung cancer cells

Leukocyte Cell-Derived Chemotaxin 2 Retards Non-Small Cell Lung Cancer Progression Through Antagonizing MET and EGFR Activities

Deoxybouvardin-glucoside induces apoptosis in non-small cell lung cancer cells by targeting EGFR/MET and AKT signaling pathway

Combined inhibition of MET and VEGF enhances therapeutic efficacy of EGFR TKIs in EGFR-mutant non-small cell lung cancer with concomitant aberrant MET activation

Pharmacogenomics of EGFR-targeted therapies in non–small cell lung cancer: EGFR and beyond

Fatty acid synthase mediates EGFR palmitoylation in EGFR mutated non‐small cell lung cancer

Multicenter real-world analysis of combined MET and EGFR inhibition in patients with non-small cell lung cancer and acquired MET amplification or polysomy after EGFR inhibition

Isothiocyanates induce oxidative stress and suppress the metastasis potential of human non-small cell lung cancer cells

Association of integrin beta1 and c-MET in mediating EGFR TKI gefitinib resistance in non-small cell lung cancer

Targeting EGFR exon 20 insertion mutations in non-small cell lung cancer

EGFR transcriptionally upregulates UTX via STAT3 in non-small cell lung cancer

The EGFR-STYK1-FGF1 axis sustains functional drug tolerance to EGFR inhibitors in EGFR-mutant non-small cell lung cancer

Lentiviral vector-mediated RBM5 overexpression downregulates EGFR expression in human non-small cell lung cancer cells

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

Deoxybouvardin targets EGFR, MET, and AKT signaling to suppress non-small cell lung cancer cells

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

Leukocyte Cell-Derived Chemotaxin 2 Retards Non-Small Cell Lung Cancer Progression Through Antagonizing MET and EGFR Activities

Deoxybouvardin-glucoside induces apoptosis in non-small cell lung cancer cells by targeting EGFR/MET and AKT signaling pathway

Combined inhibition of MET and VEGF enhances therapeutic efficacy of EGFR TKIs in EGFR-mutant non-small cell lung cancer with concomitant aberrant MET activation

Pharmacogenomics of EGFR-targeted therapies in non–small cell lung cancer: EGFR and beyond

Fatty acid synthase mediates EGFR palmitoylation in EGFR mutated non‐small cell lung cancer

Multicenter real-world analysis of combined MET and EGFR inhibition in patients with non-small cell lung cancer and acquired MET amplification or polysomy after EGFR inhibition

Isothiocyanates induce oxidative stress and suppress the metastasis potential of human non-small cell lung cancer cells

Association of integrin beta1 and c-MET in mediating EGFR TKI gefitinib resistance in non-small cell lung cancer

Targeting EGFR exon 20 insertion mutations in non-small cell lung cancer

EGFR transcriptionally upregulates UTX via STAT3 in non-small cell lung cancer

The EGFR-STYK1-FGF1 axis sustains functional drug tolerance to EGFR inhibitors in EGFR-mutant non-small cell lung cancer

Lentiviral vector-mediated RBM5 overexpression downregulates EGFR expression in human non-small cell lung cancer cells

Leukocyte Cell-Derived Chemotaxin 2 Retards Non-Small Cell Lung Cancer Progression Through Antagonizing MET and EGFR Activities

Deoxybouvardin-glucoside induces apoptosis in non-small cell lung cancer cells by targeting EGFR/MET and AKT signaling pathway

Combined inhibition of MET and VEGF enhances therapeutic efficacy of EGFR TKIs in EGFR-mutant non-small cell lung cancer with concomitant aberrant MET activation

Pharmacogenomics of EGFR-targeted therapies in non–small cell lung cancer: EGFR and beyond

Fatty acid synthase mediates EGFR palmitoylation in EGFR mutated non‐small cell lung cancer

Multicenter real-world analysis of combined MET and EGFR inhibition in patients with non-small cell lung cancer and acquired MET amplification or polysomy after EGFR inhibition

Isothiocyanates induce oxidative stress and suppress the metastasis potential of human non-small cell lung cancer cells

Association of integrin beta1 and c-MET in mediating EGFR TKI gefitinib resistance in non-small cell lung cancer

Targeting EGFR exon 20 insertion mutations in non-small cell lung cancer

EGFR transcriptionally upregulates UTX via STAT3 in non-small cell lung cancer

The EGFR-STYK1-FGF1 axis sustains functional drug tolerance to EGFR inhibitors in EGFR-mutant non-small cell lung cancer

Lentiviral vector-mediated RBM5 overexpression downregulates EGFR expression in human non-small cell lung cancer cells

Leukocyte Cell-Derived Chemotaxin 2 Retards Non-Small Cell Lung Cancer Progression Through Antagonizing MET and EGFR Activities

Deoxybouvardin-glucoside induces apoptosis in non-small cell lung cancer cells by targeting EGFR/MET and AKT signaling pathway

Combined inhibition of MET and VEGF enhances therapeutic efficacy of EGFR TKIs in EGFR-mutant non-small cell lung cancer with concomitant aberrant MET activation

Pharmacogenomics of EGFR-targeted therapies in non–small cell lung cancer: EGFR and beyond

Fatty acid synthase mediates EGFR palmitoylation in EGFR mutated non‐small cell lung cancer

Multicenter real-world analysis of combined MET and EGFR inhibition in patients with non-small cell lung cancer and acquired MET amplification or polysomy after EGFR inhibition

Isothiocyanates induce oxidative stress and suppress the metastasis potential of human non-small cell lung cancer cells

Association of integrin beta1 and c-MET in mediating EGFR TKI gefitinib resistance in non-small cell lung cancer

Targeting EGFR exon 20 insertion mutations in non-small cell lung cancer

EGFR transcriptionally upregulates UTX via STAT3 in non-small cell lung cancer

The EGFR-STYK1-FGF1 axis sustains functional drug tolerance to EGFR inhibitors in EGFR-mutant non-small cell lung cancer

Lentiviral vector-mediated RBM5 overexpression downregulates EGFR expression in human non-small cell lung cancer cells

Related objects

Reset password